Indegene IPO will open for subscription from 06 May 2024. The company aims for an issue size of ₹1,841.76 Cr through this IPO.
Company Overview
| Full name | Indegene Limited |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Company Website | https://www.indegene.com/ |
About Company
Indegene is a commercialization company focused exclusively on the global life sciences industry. Its solutions enable biopharmaceutical, emerging biotech, and medical device companies to develop products, launch them in the market, and drive sales through their life cycle more effectively and efficiently. The company’s portfolio of solutions covers a broad range of commercial, medical, regulatory, and R&D operations of life sciences companies.
The company has relationships with each of the 20 largest biopharmaceutical companies globally by revenue for FY 2023. As of 31 December 2023, Indegene had a total of 65 active clients. It had 27 clients from whom it earned between USD 1 million and USD 10 million in revenues, five clients from whom it earned between USD 10 million and USD 25 million in revenues, and three clients from whom it earned more than USD 25 million in revenues, during the 12 months ended 31 December 2023.
Indegene has developed a suite of proprietary tools and platforms, including applications that automate and create AI-based efficiencies using AI, ML, NLP, and advanced analytics capabilities. These proprietary “NEXT”-branded tools and platforms assist in driving transformation across the commercialization lifecycle of biopharmaceutical products and medical devices.
The Objectives of the Issue
- Repayment/prepayment of indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc.;
- Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.
- General corporate purposes and inorganic growth.
Indegene IPO Timetable
| IPO Opening date | 06 May 2024 |
| IPO Closing | 08 May 2024 |
| Basis of Allotment | 09 May 2024 |
| Initiation Refund | 10 May 2024 |
| Credit to Demat Account | 10 May 2024 |
| Listing Date | 13 May 2024 |
Indegene IPO details
| Issue type | Book Built Issue IPO |
| IPO issue size | ₹1,841.76 Cr – 40,746,891 shares |
| Fresh Issue | ₹760 Cr – 16,814,159 shares |
| Offer for sale | ₹1,081.76 Cr – 23,932,732 shares |
| Face value | ₹02 per share |
| Price Band | ₹430 to ₹452 per share |
| Lot size | 33 Shares |
| Employee Discount | ₹30 per share |
| Shareholding pre-issue | 222,435,091 |
| Shareholding post-issue | 239,249,250 |
| Listing Exchange | BSE & NSE |
Indegene IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 33 | ₹14,916 |
| Retail (Max) | 13 | 429 | ₹193,908 |
| S-HNI (Min) | 14 | 462 | ₹208,824 |
| S-HNI (Max) | 67 | 2,211 | ₹999,372 |
| B-HNI (Min) | 68 | 2,244 | ₹1,014,288 |
Indegene IPO Reservation Details
| QIB Shares Offered | 50% |
| NII (HNI) Shares Offered | 15% |
| Retail Shares Offered | 35% |
Indegene Financial Performance
| FY 2021 | FY 2022 | FY 2023 | 9M FY 2024 | |
| Revenue | 966.27 | 1,664.61 | 2,306.13 | 1,916.61 |
| Expenses | 768.25 | 1,417.10 | 2,001.05 | 1,644.64 |
| Net income | 149.41 | 162.82 | 266.10 | 241.90 |
| Margin (%) | 15.46 | 9.78 | 11.54 | 12.62 |
Indegene Valuations & Margins
| FY 2021 | FY 2022 | FY 2023 (Pre Issue) | FY 2024 (Post-Issue)* | |
| EPS | 6.72 | 7.32 | 11.96 | 13.48 |
| PE Ratio | – | – | 35.94 – 37.78 | 31.90 – 33.53 |
| FY 2021 | FY 2022 | FY 2023 | |
| RONW (%) | 46.04 | 21.57 | 25.02 |
| NAV | 14.59 | 34.34 | 47.82 |
| Adjusted EBITDA (%) | 27.03 | 18.79 | 19.69 |
| Debt/Equity | – | – | 0.02 |
Company Promoters
- The company is professionally managed and has no identifiable promoter
Promoter Holding
| Pre Issue Share Holding | – |
| Post Issue Share Holding | – |
Indegene IPO Lead Manager(s)
- Kotak Mahindra Capital Company Limited
- Citigroup Global Markets India Private Limited
- J.P. Morgan India Private Limited
- Nomura Financial Advisory And Securities (India) Pvt Ltd
Indegene Registrar
LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park L.B.S. Marg,
Vikhroli West, Mumbai – 400 083, Maharashtra
Telephone: +91 810 811 4949
Email: indegene.ipo@linkintime.co.in
Website: www.linkintime.co.in
Indegene Limited Contact Details
INDEGENE LIMITED
Aspen Block G4, 3rd Floor, Manyata Embassy Business Park,
Outer Ring Road, Nagawara, Bengaluru 560 045, Karnataka
Phone: +91 80 4674 4567
Email: compliance.officer@indegene.com
Website: www.indegene.com
Indegene IPO Allotment Status
Indegene IPO allotment status will be available on Link Intime’s website. Click on Link Intime IPO weblink to get allotment status.
Final thoughts
Indegene IPO is going to hit Dalal Street soon. applying for an IPO is purely a personal choice. study well about the company and subscribe if you are feeling good about the company. I hope this post will give you enough details to research the company fundamentally. learn well and make wise decisions.
Happy Investing
